Patents Examined by Adam Weidner
  • Patent number: 10894829
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: January 19, 2021
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan
  • Patent number: 10894822
    Abstract: The invention is directed to methods of treatment of Alzheimer's disease and other tauopathies, via the administration of antibodies having specificity to abnormal forms of tau protein, the antibodies showing no binding and/or reactivity to a normal tau protein and being administered under conditions and in amounts effective to prevent or treat Alzheimer's disease or other tauopathies. In certain embodiments, the antibodies are selective for soluble truncated tau protein truncated at (i) its C-terminus after the glutamic acid residue Glu391, or (ii) at the aspartic acid residue Asp421, or (iii) at its N-terminus at the aspartic acid residue Asp13, or (iv) a combination of (i)-(iii). Further aspects of the invention are directed to the administration of an immunogen comprising an abnormal tau, preferably a soluble truncated tau.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: January 19, 2021
    Assignee: TauC3 Biologics Limited
    Inventor: Daniel G. Chain
  • Patent number: 10894811
    Abstract: The present invention relates to fragments of SPLUNC1 protein that bind to calcium channels and inhibit calcium influx into airway smooth muscle and other cells. The invention further relates to methods for regulating calcium influx and treating or preventing disorders responsive to modulating calcium influx through calcium channels.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: January 19, 2021
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Robert Tarran, Tongde Wu
  • Patent number: 10889638
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: January 12, 2021
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Patent number: 10888600
    Abstract: The present disclosure provides compositions and methods useful for treating or preventing diseases or disorders where beta amyloid accumulation or aggregation contributes to the pathology or symptomology of the disease, for example Alzheimer's disease.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: January 12, 2021
    Inventors: Rudolph Emile Tanzi, Ana Griciuc
  • Patent number: 10889640
    Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: January 12, 2021
    Inventors: David Edward Ormonde Knight, Terence Seward Baker, David James McMillan, Robert Anthony Griffin, Georges Mairet-Coello, Patrick Downey, Jean-Philippe Courade
  • Patent number: 10881708
    Abstract: The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and pain.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: January 5, 2021
    Inventors: Meredith Hay, John Konhilas, Robin L. Polt, Todd Vanderah, Brittany Forte, Tally Milnes, Evan Jones, Lajos Szabo
  • Patent number: 10875908
    Abstract: The invention relates to an anti-human p53 antibody suitable for specifically binding a linear epitope which is exposed only in a conformationally altered isoform of the characteristic p53 protein of patients with Alzheimer's disease or prone to develop Alzheimer's disease or cognitive impairment during ageing. Methods and diagnostic and prognostic kits are also described.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: December 29, 2020
    Assignee: DIADEM S.R.L.
    Inventors: Maurizio Memo, Daniela Uberti
  • Patent number: 10869997
    Abstract: The present disclosure provides methods for improving drug efficacy in a patient having an obstructed airway in a lung. Such methods modulate nerve activity in the autonomic nervous system of a patient to reduce obstruction of an airway in a lung of the patient prior to administering a drug to the patient. These methods are especially useful in improving efficacies of bronchodilators in treating obstructive lung diseases, such as chronic obstructive pulmonary disease.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: December 22, 2020
    Assignee: Nuvaira, Inc.
    Inventor: Martin L. Mayse
  • Patent number: 10870709
    Abstract: The present invention relates to antibodies and binding fragments thereof that bind the ?-sheet secondary structure of a pathological monomeric or oligomeric non-fibrillar proteins without binding to the non-toxic, non-pathological forms of these proteins or peptides These antibodies and binding fragments thereof are suitable for the diagnosis, prevention, and treatment of protein conformational disorders including all amyloid diseases.
    Type: Grant
    Filed: July 22, 2017
    Date of Patent: December 22, 2020
    Inventors: Thomas M. Wisniewski, Fernando Goni
  • Patent number: 10864206
    Abstract: The invention is directed to the treatment of tauopathic neurodegenerative conditions and the underlying processes thereof. Based on the discovery that Rhes acts as a negative regulator of normal tau clearance, the compositions and methods of the invention may be applied to inhibit Rhes and reduce pathogenic tau aggregation. Rhes may be disrupted by disrupting RAS2D gene expression or reducing the abundance of Rhes protein in neurons. Additionally, post-translational modifications of Rhes may be targeted, including the disruption of Rhes farnesylation by the administration of farnesyltransferase inhibitors.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: December 15, 2020
    Assignee: The Regents of the University of California
    Inventors: Kenneth Kosik, Israel Hernandez
  • Patent number: 10864238
    Abstract: The present invention relates to a pharmaceutical composition and a food composition for preventing or ameliorating degenerative neurological disease comprising Poria cocos peel extract for preventing, or treating neurodegenerative disorders. Poria cocos peel extract which is the active ingredients contained in the composition of the present invention, has a memory ameliorating activity through inhibiting of acetylcholine esterase and a neuroprotective effect and neuron protection by inhibiting the formation of beta amyloid and tau phosphorylation and promoting NGF production. Thus, the present invention may be useful as a pharmaceutical composition for preventing or treating degenerative neurological diseases, or as a health food for the above purpose.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: December 15, 2020
    Inventors: Sang Zin Choi, Mi Won Sohn, Hyo Sang Go, Ja Young Ryu, Jin Seok Jeong, Song Hyen Choi, Eun Jin Kim, Young Woong Cho, So Young Kim
  • Patent number: 10857203
    Abstract: Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: December 8, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar, H. Steve Zhang
  • Patent number: 10836793
    Abstract: Disclosed herein are compounds for the treatment of neurodegenerative diseases and compositions comprising the same.
    Type: Grant
    Filed: December 24, 2019
    Date of Patent: November 17, 2020
    Assignee: University of South Florida
    Inventors: Jianfeng Cai, Chuanhai Cao
  • Patent number: 10836817
    Abstract: The invention provides anti-Tau antibodies and methods of using the same.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: November 17, 2020
    Assignees: AC Immune SA, Genentech, Inc.
    Inventors: Oskar Adolfsson, Kristin Ruth Wildsmith, Marcel Van Der Brug, Andreas Muhs
  • Patent number: 10815199
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Grant
    Filed: January 20, 2019
    Date of Patent: October 27, 2020
    Assignee: AstraZeneca AB
    Inventors: Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • Patent number: 10815271
    Abstract: This invention relates to inhibitory peptides which bind to ?-synuclein molecules and inhibit ?-synuclein amyloidogenic aggregation, ?-synuclein cytotoxicity, and spread of ?-synuclein. Methods of making and using the inhibitory peptides (e.g. to treat subjects having conditions or diseases that are mediated by ?-synuclein, such as Parkinson's disease, dementia with Lewy bodies, or MSA) are described.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: October 27, 2020
    Inventors: David S. Eisenberg, Smriti Sangwan, Lin Jiang
  • Patent number: 10766954
    Abstract: The invention provides therapeutic antibodies and methods for treatment of diseases associated with diseases associated with aggregation of ?-synuclein, e.g., in the brain of a subject. Such methods provide administration of therapeutic antibodies to elicit a beneficial immunogenic response against aggregation of ?-synuclein. The methods are particularly useful for prophylactic and therapeutic treatment of diseases associated with the formation of Lewy bodies, e.g., Parkinson's disease.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: September 8, 2020
    Assignee: Imago Pharmaceuticals, Inc.
    Inventors: Irene Griswold-Prenner, Karen Chen
  • Patent number: 10766953
    Abstract: Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: September 8, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Marc Mercken, Thomas Malia, Marianne Borgers, Kristof Van Kolen
  • Patent number: 10759864
    Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: September 1, 2020
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hiroyuki Sonoda, Kenichi Takahashi